Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J extends tender offer for Omrix

This article was originally published in Scrip

Executive Summary

Johnson & Johnson has extended its $438 million tender offer to buy Omrix Biopharmaceuticals, an Israeli developer of protein-based biosurgery and passive immunotherapies (Scrip Online, November 25th, 2008). The offer, originally due to expire at midnight (Eastern time) tomorrow will now end at midnight (Eastern time) on December 26th. J&J received clearance from the Israeli antitrust authorities earlier this month. The US company has tendered 23.4% of Omrix's common stock on a fully diluted basis to date.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts